An estimated 354 million people worldwide live with hepatitis B or C, and for most, testing and treatment remain beyond reach. Consequently, the World Health Organization (WHO) has set the goal of eliminating hepatitis B and C by 2030. Dr Nicole Seguy (Regional Advisor HIV, hepatitis and STIs, WHO/Europe) summarizes the existing landscape of hepatitis B and C in a global context and discusses the interventions and advances that will help to achieve this goal.
‘Hepatitis B and C: Elimination as a Public Health Goal’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- Could you give us a brief overview of the global health burden of hepatitis B and C? (00:14)
- What elimination goals have been set by the WHO? (00:41)
- What interventions in terms of prevention and testing can help meet this goal? (01:18)
- What therapeutic advances have helped make elimination feasible? (02:08)
- What barriers exist to meeting this goal and how may they be overcome? (02:52)
Disclosures: Nicole Seguy has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022.
Share this Video
Related Videos In Hepatitis
The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki […]
The Hecolin® vaccine in the prevention of hepatitis E: Iza Ciglenecki, EASL 2023
A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!